STRONG - Study of AGN1 LOEP for the Treatment of the Contralateral Femur After Fragility Fracture

Clinical Investigation of a Local Osteo-Enhancement Procedure's (LOEP) Ability to Strengthen the Contralateral Femur of Women After a Fragility Fracture of the Hip in Hong Kong

To evaluate the procedure and safety profile of the AGN1 Femoral LOEP Kit. This pilot study will be used to evaluate AGN1 Femoral LOEP treatment in a contralateral proximal femur during hip fracture repair.

Study Overview

• Status: Completed
• Conditions: Hip Fractures; Osteoporosis, Postmenopausal
• Intervention / Treatment: Device: AGN1 Femoral Local Osteo-Enhancement Procedure Kit

Detailed Description

The research will be conducted as a prospective single-center study within Hong Kong. The maximum number of subjects to be treated is twenty (20). This will be a non-randomized and non-blinded study.

Subjects having had a fragility hip fracture on one side will be treated with LOEP in the contralateral non-fractured proximal femur in the same operative session as the surgical repair of the fractured hip. A fragility fracture is defined as a fracture resulting from a fall from standing height.

All subjects will undergo hip fracture repair as recommended by the treating orthopedic surgeon. Repair may include nailing, plates, screws and hip prosthesis.

Subjects may continue to receive, or when appropriate, can be commenced on a treatment regime for osteoporosis. This decision will be made by the treating physician who will determine the best course of action for each patient. The outcome of this decision will have not affect the patient's eligibility for this trial.

Follow-up visits will be conducted at three (3) months, six (6) months, twelve (12) months, and twenty-four (24) months after the procedure.

• Study Type: Interventional
• Enrollment (Actual): 13
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Hong Kong
  • Hong Kong, Hong Kong
    • Queen Mary Hospital - Department of Orthopaedics and Traumatology

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 65 years and older (OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

1. Subject is a postmenopausal female
2. Subject has a low-energy fragility hip fracture in one hip and will undergo surgical repair of the fractured hip.
3. Subject is ≥ 65 years of age.
4. Subject has willingness, ability, and commitment to participate in baseline and follow-up evaluations for the full duration of the study.
5. Subject is capable of giving written informed consent to participate in the study.

Exclusion Criteria:

1. Subject has a prior diagnosis of secondary osteoporosis.
2. Subject has history of any hip surgery or previous hip fracture in the non-fractured hip.
3. Subject has progressive increase in undiagnosed hip pain over the previous six (6) months that in the opinion of the Investigator may suggest other underlying bone or joint pathology (e.g. osteoarthritis, fracture, etc.).
4. Subject has serum calcium levels outside the normal lab range as per local guidelines and reference ranges.
5. Subject has moderate to severe renal insufficiency as per local guidelines and reference ranges.
6. Subject has insulin-dependent diabetes mellitus (IDDM).
7. Subject has Body Mass Index (BMI) > 30.
8. Subject exhibits excessive smokeless tobacco use or excessive smoking as determined by the principal investigator*.
9. Subject exhibits excessive alcohol consumption as determined by the principal investigator*.
10. Subject has radiological evidence of gross bony or joint pathology of the non-fractured hip.
11. Subject treated with corticosteroids or systemic glucocorticoids for ten (10) days in the previous six (6) months.
12. Subject has history of oral or parenteral use of immune-suppressive drugs in the previous twelve months.
13. Subject has history of metabolic bone disease other than osteoporosis (eg. Paget's disease).
14. Subject has a history of auto-immune arthritic diseases including rheumatoid, psoriatic, or those associated with systemic lupus erythematosus, spondyloarthropathy, Reiter's Syndrome or Crohn's Disease.
15. Subject has a history of radiation therapy to the hip or pelvic region.
16. Subject has history of chemotherapy treatment for any condition within the previous five years.
17. Subject has history of any diagnosis and treatment of malignancies (excluding basal cell carcinoma) within the previous five years.
18. Subject has known allergies to implanted device.
19. Subject has severe comorbidity or poor general physical/mental health that, in the opinion of the Investigator, will not allow the subject to be a good study candidate.
20. Subject is currently enrolled in another clinical study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: NA
• Interventional Model: SINGLE_GROUP
• Masking: NONE

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
OTHER: AGN1 Treatment; Subjects who have suffered a fragility hip fracture in one hip, sign the consent form and meet the inclusion and none of the exclusion of the study will receive the AGN1 Femoral Local Osteo-Enhancement Procedure (LOEP™) in the non-fractured hip.	Device: AGN1 Femoral Local Osteo-Enhancement Procedure Kit; A procedure that is intended to replace lost bone and increase the strength of the proximal femur in individuals with osteoporosis of the femoral neck.; Other Names: AGN1 Femoral LOEP™

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of Treatment or Device Emergent Serious Adverse Events	Incidence of all serious adverse events (SAEs) occurring from the day of procedure through the twenty-four (24) month follow-up period determined to be definitely related to Femoral LOEP and/or the AGN1 device.	24 Months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of Non-Treatment Emergent Fragility Fractures	Incidence of fragility fractures unrelated to the device or procedure occurring during the follow-up period.	24 Months
Incidence of Treatment or Device Emergent Adverse Events	Incidence of all adverse events occurring from the day of procedure through the twenty-four (24) month follow-up determined to be definitely related to Femoral LOEP and/or the AGN1 device.	24 Months
Change in Bone Mineral Density between Baseline and 12 Months	Evaluation of bone mineral density (BMD) post-procedure at twelve (12) months.	12 Months
Change in Bone Mineral Density between Baseline and 24 Months	Evaluation of bone mineral density (BMD) post-procedure at twenty-four (24) months.	24 Months

Collaborators and Investigators

• Sponsor: AgNovos Healthcare, LLC
• Investigators: Principal Investigator: Christian Fang, MD, Queen Mary Hospital, Hong Kong

Publications and helpful links

Helpful Links

• Company website

Study record dates

Study Major Dates

• Study Start (ACTUAL): August 15, 2017
• Primary Completion (ACTUAL): December 31, 2020
• Study Completion (ACTUAL): December 31, 2020

Study Registration Dates

• First Submitted: August 29, 2017
• First Submitted That Met QC Criteria: August 29, 2017
• First Posted (ACTUAL): August 31, 2017

Study Record Updates

• Last Update Posted (ACTUAL): November 30, 2022
• Last Update Submitted That Met QC Criteria: November 28, 2022
• Last Verified: November 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Metabolic Diseases; Wounds and Injuries; Leg Injuries; Musculoskeletal Diseases; Bone Diseases; Femoral Fractures; Hip Injuries; Bone Diseases, Metabolic; Fractures, Bone; Hip Fractures; Osteoporosis; Osteoporosis, Postmenopausal
• Other Study ID Numbers: PST-HK-100.1

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: Yes